The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; MSD; Roche
Impact of olaparib vs physician’s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.
 
Fred Saad
Honoraria - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst)
 
Guilhem Roubaud
No Relationships to Disclose
 
Giuseppe Procopio
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer
 
Neal D. Shore
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Merck; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Bayer; Dendreon; Janssen
 
Karim Fizazi
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer; Curevac (Inst); ESSA (Inst); Janssen Oncology; Orion; Sanofi
Travel, Accommodations, Expenses - Amgen; Janssen
 
Antoine Thiery-Vuillemin
No Relationships to Disclose
 
Gabriel dos Anjos
No Relationships to Disclose
 
Gwenaelle Gravis
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Pfizer; Sanofi
 
Jae Young Joung
No Relationships to Disclose
 
Nobuaki Matsubara
Honoraria - AstraZeneca; Bayer; Chugai Pharma (Inst); Janssen; MSD
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); MSD (Inst)
 
Daniel Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; Astellas Pharma; Genentech; MLI PeerView; PER; PER; Phillips Gilmore Oncology; projects in Knowledge; Research to Practice; Research to Practice; Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Genentech; Genentech/Roche; Pfizer
 
Arnold Degboe
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Christopher Gresty
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Jinyu Kang
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Joseph E Burgents
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex